- ￥2500 - 7500
- 苏州艾洛蒙生物
- ARD0510
- 苏州
- 2025年12月17日
- human
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 抗体名：
Letaplimab（莱特利单抗）
- 抗体英文名：
Anti-Human CD47 antibody
- 靶点：
CD47, MER6, IAP, Leukocyte surface antigen CD47, Antigenic surface determinant protein OA3
- 适应物种：
human
- 保质期：
12 months
- 目录编号：
CAS：2283356-07-8
- 级别：
Research Grade
- 供应商：
苏州艾洛蒙
- 标记物：
无
- 克隆性：
单克隆
- 保存条件：
Store at -20°C for 12 months (Avoid repeated freezing and thawing)
- 形态：
Liquid
- 亚型：
Human IgG4, κ
- 规格：
1mg/5mg
| 规格： | 1mg | 产品价格： | ￥2500.0 |
|---|---|---|---|
| 规格： | 5mg | 产品价格： | ￥7500.0 |
Letaplimab (IBI-188) 一种人源 IgG4 单克隆抗 CD47 抗体。CD47 在癌细胞中过表达，是 SIRPα 的配体。Letaplimab 增强肿瘤细胞吞噬作用。
Letaplimab (IBI-188) is a human IgG4 anti-CD47 monoclonal antibody. CD47 is overexpressed on cancer cells, it is a ligand for SIRPα. Letaplimab enhances tumor cell phagocytosis
anti-CD47 monoclonal antibody IBI188
A human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47 with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-CD47 monoclonal antibody IBI188 selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.
CD47 is overexpressed in various types of cancers and it can directly bind with SIRPα, which is mainly located on macrophages. The binding of CD47-SIRPα transmits a “don't eat me” signal, which can prevent cancer cells from immune clearance. In this case, the comprehensive understandings of the regulation of CD47 in cancer cells are essential for further developments. In this review, based on the current reports, we summarized that CD47 expression could be regulated by cytokines, oncogenes, microRNAs and enzymes in cancer cells. Likewise, CD47 expression could be regulated at the transcriptional level, post-transcriptional level, post-translational modification level, etc. However, further studies are required to determine other factors that regulate CD47 expression.
•Cytokines, oncogenes, microRNAs and enzymes regulate CD47 expression in cancer.
•CD47 expression could be regulated at the transcriptional, post-transcriptional and post-translational modification level.
•Further studies are required to determine other factors that regulate CD47 expression.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
